Invitra CBSC™ is a minimally manipulated human tissue allograft suspension derived from umbilical cord blood. Invitrx Therapeutics utilizes a proprietary process to preserve the tissue characteristics and properties.
Stem cells were first identified in cord blood over 40 years ago. Since then cord blood has been used routinely for hematopoietic stem cell transplantation. Cord blood contains a mixed population of cells, including hematopoietic stem cells (HSC) and mesenchymal stems cells (MSC). These cells have the capacity to self-renew, release growth factors, and further develop into more specialized cells. These cells have also been associated with contributing to tissue homeostasis, anti-inflammatory responses and antioxidant effects.
Invitra CBSC™ is processed from donated umbilical cords from full term deliveries. All donors are pre-screened and undergo comprehensive testing that includes:
- Behavioral risk assessment
- Physical assessment
- Donor medical history
- Communicable disease testing